Contrasting Drugs Made In America Acquisition (NASDAQ:DMAA) and Check Point Software Technologies (NASDAQ:CHKP)

Check Point Software Technologies (NASDAQ:CHKP – Get Free Report) and Drugs Made In America Acquisition (NASDAQ:DMAA – Get Free Report) are both technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Institutional and Insider Ownership

98.5% of Check Point Software Technologies shares are owned by institutional investors. 29.0% of Check Point Software Technologies shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Check Point Software Technologies and Drugs Made In America Acquisition”s revenue, earnings per share and valuation.

Check Point Software Technologies has higher revenue and earnings than Drugs Made In America Acquisition.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Check Point Software Technologies and Drugs Made In America Acquisition, as reported by MarketBeat.

Check Point Software Technologies currently has a consensus target price of $149.48, suggesting a potential upside of 17.58%. Given Check Point Software Technologies’ stronger consensus rating and higher probable upside, research analysts plainly believe Check Point Software Technologies is more favorable than Drugs Made In America Acquisition.

Risk & Volatility

Check Point Software Technologies has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500.

Profitability

This table compares Check Point Software Technologies and Drugs Made In America Acquisition’s net margins, return on equity and return on assets.

Summary

Check Point Software Technologies beats Drugs Made In America Acquisition on 10 of the 10 factors compared between the two stocks.

About Check Point Software Technologies

(Get Free Report)

Check Point Software Technologies Ltd. develops, markets, and supports a range of products and services for IT security worldwide. The company offers a multilevel security architecture, cloud, network, mobile devices, endpoints information, and IOT solutions. It provides Check Point Infinity Architecture, a cyber security architecture that protects against fifth generation cyber-attacks across various networks, endpoint, cloud, workloads, Internet of Things, and mobile. In addition, the company offers security gateways and software platforms that support small and medium sized business. Further, it provides cloud network security, cloud native application protection, security and posture management, cloud identity and entitlement, cloud workload protection, cloud detection and response, and cloud web application protection for web applications and APIs; and Check Point Harmony that delivers endpoint and secure connectivity for remote user access. Additionally, the company offers technical customer support programs and plans; professional services in implementing, upgrading, and optimizing Check Point products comprising design planning and security implementation; and certification and educational training services on Check Point products. It sells its products through distributors, resellers, system integrators, original equipment manufacturers, and managed security service providers. Check Point Software Technologies Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

About Drugs Made In America Acquisition

(Get Free Report)

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.